default author photo

Gale Smith

Novavax, Inc.

United States

SCHOLARLY PAPERS

3

DOWNLOADS

171

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines

Number of pages: 45 Posted: 01 Feb 2021
Duke University - Duke Human Vaccine Institute, Duke University - Department of Surgery, Duke University - Department of Surgery, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Los Alamos National Laboratory - Theoretical Biology and Biophysics, Moderna, Inc., Novavax, Inc., Novavax, Inc., Novavax, Inc., Los Alamos National Laboratory - Theoretical Biology and Biophysics and Duke University - Duke Human Vaccine Institute
Downloads 81 (796,622)

Abstract:

Loading...

2.

Covid-19 Vaccine (Nvx-Cov2373 and Nvx-Cov2540) Doses and Virus Strain Match Impact Sex- and Age-Specific Immunity and Protection in Mice

Number of pages: 27 Posted: 18 Feb 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Novavax, Inc., affiliation not provided to SSRN, Novavax, Inc., Johns Hopkins University - Department of Molecular Microbiology and Immunology and Johns Hopkins University - Department of Molecular Microbiology and Immunology
Downloads 59 (970,490)

Abstract:

Loading...

aging, estradiol, antibody secreting cells, testosterone, follicular helper T cells

3.

Collaboration between the Fab and Fc Contribute to Maximal Protection Against SARS-CoV-2 Following NVX-CoV2373 Subunit Vaccine with Matrix-M™ Vaccination

Number of pages: 41 Posted: 06 Apr 2021
Ragon Institute of MGH, MIT and Harvard, Novavax, Inc., Novavax, Inc., Ragon Institute of MGH, MIT and Harvard, Ragon Institute of MGH, MIT and Harvard, Massachusetts Institute of Technology - Department of Biological Engineering, Ragon Institute of MGH, MIT and Harvard, Texas Biomedical Research Institute, Texas Biomedical Research Institute, Novavax, Inc., Ragon Institute of MGH, MIT and Harvard, Ragon Institute of MGH, MIT and Harvard, Novavax, Inc., Novavax, Inc., University of Maryland - School of Medicine, University of Maryland - School of Medicine, University of Maryland - School of Medicine, Duke University - Duke Human Vaccine Institute, La Jolla Institute for Allergy and Immunology (LIAI), La Jolla Institute for Allergy and Immunology (LIAI), Icahn School of Medicine at Mount Sinai - Department of Microbiology, Icahn School of Medicine at Mount Sinai - Department of Microbiology, La Jolla Institute for Allergy and Immunology (LIAI) - Center for Infectious Disease and Vaccine Research, Massachusetts Institute of Technology (MIT) - Department of Biological Engineering, Novavax, Inc., Novavax, Inc., Novavax, Inc., Novavax, Inc., Novavax, Inc., Novavax, Inc. and MassachusettsGeneral Hospital - Ragon Institute of MGH, MIT and Harvard
Downloads 31 (1,304,549)
Citation 1

Abstract:

Loading...

NVX-CoV2373 vaccine, Matrix-M™ adjuvant, SARS-CoV-2 spike glycoprotein, non-human primate, COVID-19